Company profile
Immunitas Therapeutics
Privately held: no public share price (EDGAR filings are Reg-D private placements only (D); no registered class of securities [resolved 2026-08-05 by resolve-null-is-public; source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001879910])
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | CD161 (KLRB1)Monoclonal antibody | Non-Small Cell Lung CancerHR+/HER2- Breast Cancer HR+/HER2- Metastatic Breast Cancer |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.